beta-alanine has been researched along with Chronic Kidney Diseases in 10 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "It is a case report of bleeding when using dabigatran in patient with renal failure caused by the concurrent use of spironolactone and angiotensin-converting enzyme (ACE) inhibitors." | 7.79 | [Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors]. ( Andreev, DA; Gappoeva, ZK; Giliarov, MIu; Sychev, DA, 2013) |
| "Novel oral anticoagulants (NOACs) including apixaban, dabigatran and rivaroxaban have been approved by international regulatory agencies to prevent venous thromboembolism as well as treat atrial fibrillation and venous thromboembolism in individuals with chronic kidney disease (CKD)." | 4.91 | Comparison of novel oral anticoagulants versus vitamin K antagonists in patients with chronic kidney disease. ( Harel, Z; Perl, J; Sood, MM, 2015) |
| "It is a case report of bleeding when using dabigatran in patient with renal failure caused by the concurrent use of spironolactone and angiotensin-converting enzyme (ACE) inhibitors." | 3.79 | [Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors]. ( Andreev, DA; Gappoeva, ZK; Giliarov, MIu; Sychev, DA, 2013) |
| " Much remains to be learned about the optimal use of the novel oral anticoagulants in CKD patients; additional studies about optimal dosing of the novel oral anticoagulants and frequency of monitoring renal function in CKD patients with atrial fibrillation are needed." | 2.49 | Stroke prevention in atrial fibrillation patients with chronic kidney disease. ( Brimble, KS; Eikelboom, JW; Hart, RG; Ingram, AJ; McMurtry, MS, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andreev, DA | 1 |
| Gappoeva, ZK | 1 |
| Sychev, DA | 1 |
| Giliarov, MIu | 1 |
| Ahmad, Y | 1 |
| Lip, GY | 1 |
| Hart, RG | 1 |
| Eikelboom, JW | 1 |
| Brimble, KS | 1 |
| McMurtry, MS | 2 |
| Ingram, AJ | 1 |
| Lowe, MP | 1 |
| Collins, J | 1 |
| Yehia, M | 1 |
| Eaddy, N | 1 |
| Ribés-Cruz, JJ | 1 |
| Torregrosa-Maicas, I | 1 |
| Ramos-Tomás, C | 1 |
| Solís-Salguero, MA | 1 |
| Puchades-Montesa, MJ | 1 |
| González-Rico, MA | 1 |
| Juan-García, I | 1 |
| Tomás-Simó, P | 1 |
| Tejedor-Alonso, S | 1 |
| Zambrano-Esteves, P | 1 |
| Miguel-Carrasco, A | 1 |
| Ware, KM | 1 |
| Vance, JC | 1 |
| Muni, N | 1 |
| Hebert, LA | 1 |
| Satoskar, AA | 1 |
| Nadasdy, G | 1 |
| Ivanov, I | 1 |
| Nadasdy, T | 1 |
| Rovin, BH | 1 |
| Brodsky, SV | 1 |
| Olesen, JB | 1 |
| Sørensen, R | 1 |
| Hansen, ML | 1 |
| Lamberts, M | 1 |
| Weeke, P | 1 |
| Mikkelsen, AP | 1 |
| Køber, L | 1 |
| Gislason, GH | 1 |
| Torp-Pedersen, C | 1 |
| Fosbøl, EL | 1 |
| Verma, A | 1 |
| Cairns, JA | 1 |
| Mitchell, LB | 1 |
| Macle, L | 1 |
| Stiell, IG | 1 |
| Gladstone, D | 1 |
| Connolly, S | 1 |
| Cox, JL | 1 |
| Dorian, P | 1 |
| Ivers, N | 1 |
| Leblanc, K | 1 |
| Nattel, S | 1 |
| Healey, JS | 1 |
| Harel, Z | 1 |
| Sood, MM | 1 |
| Perl, J | 1 |
| Zaleski, M | 1 |
| Dabage, N | 1 |
| Paixao, R | 1 |
| Muniz, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Can Rivaroxaban Lead to Anticoagulation-Related Nephropathy?[NCT02900170] | 8 participants (Actual) | Observational | 2016-07-31 | Completed | |||
| Pharmacokinetics and Pharmacodynamics of Apixaban in End-stage Renal Disease Patients on Hemodialysis[NCT02672709] | Phase 4 | 7 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| The Effect of Nurse Practitioner-Led Care on Health Related Quality Of Life in Adult Patients With Atrial Fibrillation - A Randomized Trial[NCT02745236] | 150 participants (Actual) | Interventional | 2016-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Primary endpoint - Incidence of ARN is the primary outcome of this study and this is based on a documentation of AKI (defined as an increase in baseline serum creatinine ≥ 0.3 mg/dL), in the absence of any other obvious etiology for the AKI identified after a standard clinical evaluation and work up by the patient's primary care physician, cardiologist or nephrologist. This incidence will be expressed as a percentage. (NCT02900170)
Timeframe: 6 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Participants | 0 |
3 reviews available for beta-alanine and Chronic Kidney Diseases
| Article | Year |
|---|---|
Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; C | 2013 |
Stroke prevention in atrial fibrillation patients with chronic kidney disease.
Topics: Administration, Oral; Age Factors; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine | 2013 |
Comparison of novel oral anticoagulants versus vitamin K antagonists in patients with chronic kidney disease.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Humans; Rena | 2015 |
7 other studies available for beta-alanine and Chronic Kidney Diseases
| Article | Year |
|---|---|
[Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Benzimidazoles; beta-Alanine; C | 2013 |
Reversal of dabigatran with haemodialysis in a patient requiring decompression for cord compression from an epidural abscess.
Topics: Aged; Anti-Bacterial Agents; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood | 2013 |
Dabigatran-induced upper intestinal bleeding in a patient with chronic kidney disease.
Topics: Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabetes Mellitus, | 2013 |
Oral warfarin and the thrombin inhibitor dabigatran increase blood pressure in rats: hidden danger of anticoagulants?
Topics: Acetylcysteine; Animals; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; bet | 2015 |
Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; be | 2015 |
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2014 |
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2014 |
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2014 |
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
Topics: Algorithms; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanin | 2014 |
Dabigatran-induced hyperkalemia in a renal transplant recipient: a clinical observation.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Hyperkalemia; Kidney Transplantatio | 2013 |